Validating Gene Signatures in mCRPC

May 6, 2014
William K. Oh, MD

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the process of validating a whole-blood prognostic signature in metastatic castration-resistant prostate cancer (mCRPC).

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the process of validating a whole-blood prognostic signature in metastatic castration-resistant prostate cancer (mCRPC).

Clinical Pearls:

  • A previously identified six-gene signature, (ABL2, SEMA4D, ITGAL, C1QA, TIMP1, CDKN1A) was likely derived from immune cells, not cancer
  • Since this signature was found to be prognostic, this could indicate that the body’s reaction to cancer is as important as the cancer itself
  • The primary question now is whether or not this data can be easily quantified by measuring a biomarker in the blood reproducibly in a commercially available test
  • Work is ongoing with diagnostic companies to commercialize the six-gene prognostic signature